Leucocyte depletion of the blood supply - How will patients benefit?

British Journal of Haematology

Volumn 110, Issue 2, 2000, Pages 256-272

  Williamson, L M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cytomegalovirus; Human T cell leukaemia lymphoma virus; Immunomodulation; Leucocyte depletion; New variant Creutzfeldt Jakob disease

Indexed keywords

BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOMODULATION; LEUKOCYTE TRANSFUSION; LEUKOPENIA; PRACTICE GUIDELINE; PRION DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; FILTRATION; HLA ANTIGENS; HUMANS; INFECTION; INFECTION CONTROL; LYMPHOCYTE DEPLETION; POSTOPERATIVE COMPLICATIONS; PRIONS; QUALITY CONTROL; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033845096     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02062.x     Document Type: Review

References (169)

1. Automatic volumetric capillary cytometry for counting white cells in white cell-reduced plateletpheresis components
2. A case of transfusion associated graft versus host disease not prevented by white cell-reduction filters
3. Reduction of HTLV-I-infected cells in blood by leukocyte filtration
4. Clinical and laboratory factors associated with platelet transfusion refractoriness: A case-control study
5. Effect of perioperative transfusions on recurrence of colorectal cancer
6. A prospective randomised study of three types of platelet concentrates in patients with haematological malignancy: Corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions
7. Transmission dynamics and epidemiology of BSE in British cattle
8. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
9. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage
10. Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry
11. + stem cell enumeration: Experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation
12. Clinical factors influencing the efficacy of pooled platelet transfusions
13. Infectious human herpesvirus 8 in a healthy North American blood donor
14. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse?
15. Allogeneic blood transfusion-induced enhancement of tumour growth in two animal models showing amelioration by leukodepletion and passive transfer using spleen cells
16. Bacterial contamination of cellular blood components
17. Immunomodulation by blood transfusion: An evolving scientific and clinical challenge
18. Influence of antibiotics on posttransfusion platelet increment
19. White cell reduction in blood from donors with sickle cell trait
20. Biologic effects of leukocytes present in transfused cellular blood products
21. Growth enhancement of established tumours by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion; the importance of the timing of the leuko-depletion
22. The effect of unmodified or prestorage white cell-reduced allogeneic red cell transfusions on the immune responsiveness of orthopedic surgery patients
23. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant
24. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
25. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
26. Human spongiform encephalopathy: The National Institutes of Health series of 300 experimentally transmitted cases
27. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy
28. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent
29. Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom
30. Effects of white cell reduction on the resistance of blood components to bacterial multiplication
31. Blood transfusions and prognosis in colorectal cancer
32. The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs
33. Quality of leucodepleted plasma produced by whole blood filtration
34. Evaluation of a novel filter for leucocyte depletion of fresh plasma
35. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair
36. A prospective study of symptomatic bacteremia following platelet transfusion and of its management
37. Alloimmunisation against the MHC antigens after platelet transfusions is due to contaminating leucocytes in the platelet suspension
38. Initiation of a national study to detect bacteria-associated transfusion reactions
39. Wider benefits of leukodepletion of blood products
40. Predicting the CJD epidemic in humans
41. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
42. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors
43. Impact of leukodepletion on infections other than cytomegalovirus
44. Prion protein expression in human leukocyte differentiation
45. Transfusion transmission of retroviruses: Human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1
46. Relative importance of immune and non-immune causes of platelet refractoriness
47. Practical guidelines for process validation and process control of white cell-reduced blood components: Report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)
48. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components
49. Mononuclear cell microchimerism and the immunomodulatory effect of transfusion
50. Current research on the immunomodulatory effect of allogeneic blood transfusion
51. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components
52. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood
53. Blood transfusion and post operative infection in orthopedic patients
54. Keeping an open mind about prions
55. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions
56. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group
57. KS-associated herpesvirus-like DNA sequences after allogeneic bone-marrow transplantation
58. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration
59. A comparative analysis of different methods for routine blood component preparation
60. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions
61. The role of the plasma from platelet concentrates in transfusion reactions
62. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery
63. Blood transfusion - Modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery
64. The same prion strain causes vCJD and BSE
65. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples
66. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units
67. Transfusion of the HIV-seropositive patient; immunomodulation, viral reactivation and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6, 7 and 8
68. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease
69. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
70. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: A prospective study
71. Hypotensive reactions: A previously uncharacterized complication of platelet transfusion?
72. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets
73. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery
74. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
75. Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits
76. The highly sensitized patient: Etiology, impact and management
77. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia
78. A crucial role for B cells in neuroinvasive scrapie
79. PrP expression in B-lymphocytes is not required for prion neuroinvasion
80. Transfusion transmission of human T-lymphotropic virus types I and II: Serologic and polymerase chain reaction results in recipients identified through look-back investigations
81. Microvesicles in blood components: Laboratory and clinical aspects
82. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders
83. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts
84. Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV-infected individuals. Implications for prevention of CMV transmission
85. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time
86. High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans
87. A multicentric seroepidemiological survey of HTLV-I/II in Italy
88. Transfusional risk of HHV-8 infection
89. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analysis of unconfounded studies
90. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group
91. The distribution of normal prion protein in human blood
92. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions
93. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion
94. Transmission to animals of Creutzfeldt-Jakob disease from human blood
95. + bone marrow progenitors
96. Activation during preparation of therapeutic platelets affects deterioration during storage: A comparative flow cytometric study of different production methods
97. Post operative infections following autologous and homologous blood transfusions
98. Septic reactions to platelet transfusions
99. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia
100. Guidelines on the clinical use of leucocyte-depleted blood components
101. Universal leucocyte depletion of blood components - Con
102. Infection or suspected infection after hip replacement with autologous or homologous blood transfusion
103. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates
104. Reactions to platelet transfusion: The effect of the storage time of the concentrate
105. Increased tumor necrosis factor α (TNFα) interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates relationship between TNFα and IL-6 levels and febrile transfusion reactions
106. Influence of clinical status on the efficiency of stored platelet transfusion
107. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study
108. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: Seroconversion in recipients
109. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - A randomized trial
110. Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia
111. Febrile neutropenia contributes to underreporting of potential septic platelet transfusion reactions
112. Effect of blood transfusions on subsequent kidney transplants
113. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients
114. Prevention of transfusion-transmitted cytomegalovirus infection
115. Prophylaxis and prevention of CMV infection in BM allograft recipients. Leucodepleted platelets are equivalent to those from CMV seronegative donors
116. Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients
117. Analysis of leucocyte subset specific expression markers using Taqman real-time quantitative PCR
118. 27-30 is a normal soluble prion protein fragment released by human platelets
119. Prion protein released by platelets
120. Transfusion-related acute lung injury: A neglected serious complication of haemotherapy
121. Preliminary assessment of whole-blood, red-cell and platelet-leucodepleting filters for possible induction of prion release by leucocyte fragmentation during room temperature processing
122. In vivo cellular tropism of human T-cell leukemia virus type 1
123. Effective prophylaxis against platelet refractoriness in multi-transfused patients by use of leukocyte-free blood components
124. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity
125. Activation of the contract system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received the filtered platelets
126. Transfusion-related acute lung injury
127. Latent and persistent infections of monocytes and macrophages
128. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunisation and refractoriness: A randomized prospective study
129. Removal of cytomegalovirus DNA from donor blood by filtration
130. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
131. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
132. White cell subsets in apheresis and filtered platelet concentrates
133. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells
134. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988)
135. In vitro and in vivo effects of prestorage filtration of apheresis platelets
136. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery
137. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice
138. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions
139. A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery
140. Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia
141. The impact of new variant Creutzfeldt-Jakob disease on blood transfusion practice
142. New-variant Creutzfeldt-Jakob disease: The risk of transmission by blood transfusion
143. Perioperative blood transfusion and cancer recurrence meta-analysis for explanation
144. Transfusion-associated cancer recurrence and postoperative infection, meta-analysis of randomized controlled clinical trials
145. Allogeneic blood transfusion, hospital charges, and length of hospitalization. A study of 487 consecutive patients undergoing colorectal cancer resection
146. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery, a randomized clinical trial
147. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective randomized trial
148. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters
149. Prevention of donor-specific T-cell unresponsiveness after buffy-coat-depleted blood transfusion
150. Pretransplantation blood transfusion revisited
151. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation
152. Long-term detection of microchimaerism in peripheral blood after pre-transplantation blood transfusion
153. A new variant of Creutzfeldt-Jakob disease in the UK
154. New variant Creutzfeld-Jacob disease and leucocyte depletion of blood components
155. Transfusion-associated graft-versus-host disease and its prevention
156. Bedside filtration of blood products in the prevention of HLA alloimmunisation - A prospective randomised study
157. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease
158. Leukocyte depletion of whole blood and red cells from donors with hemoglobin sickle trait
159. Serious hazards of transfusion (SHOT) initiative: Analysis of the first two annual reports
160. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets
161. Codon 129 genotype and new variant Creutzfeld-Jakob disease
162. Spread of human cytomegalovirus (HCMV) after infection of human hematopoietic progenitor cells. Model of HCMV latency